Here we report a case of a CML patient in whom a ABL point mutation (Leu387Trp or L387W) was identified during imatinib treatment. The in vitro characterization of the mutation response to TKIs does not suggest a significant role of the Leu387Trp in imatinib resistance acquisition. Nevertheless, cytogenetic and molecular responses were achieved only after switch to bosutinib.
| INTRODUCTION
Here we report a case of a CML patient in whom a ABL point mutation (Leu387Trp or L387W) was identified during imatinib treatment. The in vitro characterization of the mutation response to TKIs does not suggest a significant role of the Leu387Trp in imatinib resistance acquisition. Nevertheless, cytogenetic and molecular responses were achieved only after switch to bosutinib.
Chronic myeloid leukemia (CML) is a myeloproliferative disorder driven by the presence of the BCR/ABL1 fusion gene on the Philadelphia chromosome, originated from the reciprocal translocation t(9;22)(q34.1;q11.2). BCR/ABL1 protein is characterized by enhanced and constitutive tyrosine kinase activity, which leads to the deregulation of downstream signaling pathways, mainly affecting cell cycle regulation, proliferation, and apoptosis. 1 CML treatment is based on tyrosine kinase inhibitors (TKIs), giving patients a great improvement in survival and quality of life. 2 Nevertheless, some patients develop secondary resistance during treatment, frequently caused by appearance of point mutations in the kinase domain. 3 More than 100 ABL mutations have been associated with TKI resistance, but not all of them have been characterized in terms of sensitivity to TKIs.
Here we report a case of a young woman in whom a point mutation on ABL (Leu387Trp) was identified during imatinib treatment, with lack of cytogenetic response and the need to change TKI. This mutation was reported previously ABL1 transcript (115,16% IS; Figure 1A) ; the patient was assigned to intermediate risk by Sokal score (0.84) and low risk by Hasford score (398). The patient was initially treated with hydroxyurea, followed by 400 mg/d of imatinib, which was suspended for 4 weeks after 1 month of treatment because of severe neutropenia.
Analysis at 3 months showed lack of both cytogenetic (46,XX t(9;22) 100%) and molecular (BCR/ABL1 43,73% IS) responses. However, mutational analysis of the BCR/ABL1 gene was negative. After 6 months of treatment, the patient achieved a partial cytogenetic response (46,XX t(9;22) 33%) with an MR1 level of molecular response (BCR/ABL1 9.066% IS).
The patient was admitted in 2018 to our center, where MR1 molecular response was confirmed (BCR/ABL 2.82% IS). Thus, she continued on the same dose of imatinib, as it was globally well tolerated.
After 9 months of therapy, the bone marrow aspirate revealed the presence of an atypical translocation in 2 out of 25 analyzed metaphases, the t(9;22;10), and the cytogenetic response was still partial (8%). Therefore, imatinib dose was increased to 600 mg/d.
At the same time, sequencing of BCR/ABL1 gene revealed a point mutation in the BCR/ABL catalytic domain: Leucine 387 was replaced by tryptophan (Leu387Trp). Because of a further increase in PCR values (3.03% IS vs 2.00% IS), the patient was switched to bosutinib, 400 mg/d.
The bone marrow aspirate at 12 months from the diagnosis showed no atypical cells; cytogenetic analysis revealed a complete response with no evidence of t(9;22) or t(9;22;10) positive cells. Moreover, molecular response reached MR2 level at the last two follow-up (BCR/ABL1/ ABL ratio = 0.52% IS and 0.18% IS). The patient is continuing bosutinib treatment (400 mg/d).
| DISCUSSION
In order to biologically characterize this mutation, we stably overexpressed BCR/ABL1, wild type (WT), and Leu387Trp, in the IL3-dependent murine pro-B cell line, Ba/F3. Expression of BCR/ABL1 fusion protein conferred IL3-independent growth to the cells. The presence of the Leu387Trp substitution was confirmed by Sanger sequencing (not shown). BCR/ABL1-Leu387Trp transcript levels were comparable to the WT as well as to two additional mutants previously described 5 (Leu384Met and His396Arg) that were used as comparators, since they hit residues in the same region of the kinase, that is, the activation loop. The first aim of this study was to identify any sensitivity difference to imatinib exerted by the Leu387Trp mutation compared to the WT and to evaluate if it had the same sensitivity/resistance profile of other known mutations. Surprisingly, the Leu387Trp cell line did not show any significant difference in the response to imatinib treatment, as shown by comparable IC50 values (WT: 0.45 µmol/L; Leu387Trp: 0.36 µmol/L; Figure 1B and Table 1 ). This was further confirmed by Western blot analysis performed on total cell lysate from Ba/F3_BCR/ABL1_WT and Ba/F3_BCR/ ABL1_Leu387Trp cell lines. BCR/ABL1 phosphorylation is only visible at low concentration treatments, thus confirming the efficacy of the treatment. Moreover, the inhibition pattern on BCR/ABL1_Leu387Trp is comparable to the WT one, again confirming the same sensitivity trait of the Leu387Trp mutant compared to the WT.( Figure 1C) . As a comparison, Ba/F3_BCR/ABL1 cells carrying mutations in close vicinity (Leu384Met and His396Arg) did show a significant IC50 shift ( Figure 1B) .
Next, we evaluated the effects of other tyrosine kinase inhibitors (bosutinib, 6 dasatinib, 7 nilotinib, 8 ponatinib, 9 and PF-114 10 ) on the Ba/F3_BCR/ABL1_ Leu387Trp cell line. Interestingly, the mutated cell line showed a moderate resistance to dasatinib and nilotinib, with ~2.4-fold and ~3.8-fold increase resistance compared to the WT, respectively. (Table 1) .
Taken together, these results do not seem to suggest a significant role of the Leu387Trp mutation in the acquisition of imatinib resistance. Therefore, the Leu387Trp mutation can be considered as a mutation that was selected by imatinib treatment and gave the cells a certain advantage together with some other unknown factor. Moreover, we cannot rule out the in vivo existence of low-level clones with different BCR/ABL1 mutations. The advantage provided by the presence of the Leu387Trp mutation may be so subtle that it is not appreciable in in vitro models, but it may contribute to other complex mechanisms that eventually lead to imatinib resistance in vivo. Alternatively, it may represent a "passenger" mutation that was acquired together with other unknown alterations that caused resistance to imatinib. It is therefore hard to speculate which other factors are involved. Since the resistance to imatinib was successfully overcome by bosutinib, other kinases might be activated, which ultimately lead to the activation of by-pass pathways.
In conclusion, we present a case of Philadelphia-positive CML patient that responded poorly to imatinib, developed an activation loop mutation that, per sé, does not seem to confer significant resistance in vitro, and was successfully treated with second-line bosutinib, which achieved MR2 remission.
The importance of this mutation may not be huge from a biological point of view; however, we believe it is important for a physician who finds out that a patient is carrying such mutation during imatinib treatment, to know that bosutinib treatment will provide better outcomes. These results will provide useful insights to physician treating CML patients with this rare mutation in the future, and they should also advise against automatically considering a new mutation in a CML patient as the cause of TKI resistance.
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